Latest News Archive
Please select Category, Year, and then Month to display items
01 February 2024
|
Story Lacea Loader
|
Photo SUPPLIED
Prof Prince Ngobeni, newly appointed Campus Principal of the UFS Qwaqwa Campus.
The University of the Free State (UFS) has appointed Prof Prince Ngobeni as Principal of the Qwaqwa Campus as from 1 February 2024.
Prof Ngobeni completed his first qualification in Analytical Chemistry at the then Technikon North-West before furthering his studies at the then Technikon Pretoria. He completed a DTech in Chemistry at the Tshwane University of Technology (TUT) in 2003. In 2016, he enrolled for a Doctor of Business Administration in Higher Education at the University of Bath in England.
His lecturing career began at TUT in 1995 where he progressed from Head of Department: Chemistry in 2003 to Associate Dean: Faculty of Science in 2010, before being appointed as Executive Dean of the Faculty of Sciences at TUT in 2015 – a position he held until 2023. He also served as Interim Campus Rector of TUT’s Pretoria Campus from 2018 to 2020.
“With extensive years of academic leadership experience, Prof Ngobeni has the experience required to guide the Qwaqwa Campus towards the university’s Vision 130. The campus is already recognised as a leader in some of its unique research fields, and Prof Ngobeni’s strong research background will be valuable in this regard,” says Prof Francis Petersen, Vice-Chancellor and Principal of the UFS.
Prof Ngobeni is a member of several professional bodies in his field of expertise, including MatTEK at the Council for Scientific and Industrial Research (CSIR), the South African Chemical Institute (SACI), the Society for Atomic Spectroscopy, and the South African Council for Natural Scientific Professions (SACNASP). During his career, he has also secured research funding for individual projects and international partnerships. Prof Ngobeni also initiated chemistry practical sessions for local schools and participated in the Technology Station in Chemicals project, which offers a wide range of services designed to assist small and medium enterprises (SMEs) in the chemical sector.
His substantial list of publications in journals and books covers a range of chemistry-related and managerial topics. He is also a well-versed presenter at local and international conferences.
“The Qwaqwa Campus has experienced major developments in recent years; I look forward to further contributing to the growth of the campus and to support the university in achieving its Vision 130,” says Prof Ngobeni.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004